Cargando…
Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
Phosphodiesterase-4 inhibitors (PDE4Is) are potent anti-inf lammatory agents and roflumilast has been used to prevent acute exacerbation of chronic obstructive pulmonary disease (COPD). Roflumilast decreases neutrophil migration, restores cystic fibrosis transmembrane conductance regulator activity,...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061018/ https://www.ncbi.nlm.nih.gov/pubmed/32131571 http://dx.doi.org/10.3904/kjim.2020.035 |
_version_ | 1783504333869940736 |
---|---|
author | Rhee, Chin Kook Kim, Deog Kyeom |
author_facet | Rhee, Chin Kook Kim, Deog Kyeom |
author_sort | Rhee, Chin Kook |
collection | PubMed |
description | Phosphodiesterase-4 inhibitors (PDE4Is) are potent anti-inf lammatory agents and roflumilast has been used to prevent acute exacerbation of chronic obstructive pulmonary disease (COPD). Roflumilast decreases neutrophil migration, restores cystic fibrosis transmembrane conductance regulator activity, and recovers glucocorticoid effects. A forced expiratory volume in 1 second of < 50%, a chronic bronchitis phenotype, high blood eosinophil levels, and a history of hospitalization are biomarkers for predicting responses to roflumilast. Adverse effects are common in clinical practice. An inhaled PDE4I has recently been developed and is under clinical trial. CHF6001 and RPL554 exhibit promise and may be future treatment options for COPD. |
format | Online Article Text |
id | pubmed-7061018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-70610182020-03-16 Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease Rhee, Chin Kook Kim, Deog Kyeom Korean J Intern Med Review Phosphodiesterase-4 inhibitors (PDE4Is) are potent anti-inf lammatory agents and roflumilast has been used to prevent acute exacerbation of chronic obstructive pulmonary disease (COPD). Roflumilast decreases neutrophil migration, restores cystic fibrosis transmembrane conductance regulator activity, and recovers glucocorticoid effects. A forced expiratory volume in 1 second of < 50%, a chronic bronchitis phenotype, high blood eosinophil levels, and a history of hospitalization are biomarkers for predicting responses to roflumilast. Adverse effects are common in clinical practice. An inhaled PDE4I has recently been developed and is under clinical trial. CHF6001 and RPL554 exhibit promise and may be future treatment options for COPD. The Korean Association of Internal Medicine 2020-03 2020-02-28 /pmc/articles/PMC7061018/ /pubmed/32131571 http://dx.doi.org/10.3904/kjim.2020.035 Text en Copyright © 2020 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Rhee, Chin Kook Kim, Deog Kyeom Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease |
title | Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease |
title_full | Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease |
title_fullStr | Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease |
title_full_unstemmed | Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease |
title_short | Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease |
title_sort | role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061018/ https://www.ncbi.nlm.nih.gov/pubmed/32131571 http://dx.doi.org/10.3904/kjim.2020.035 |
work_keys_str_mv | AT rheechinkook roleofphosphodiesterase4inhibitorsinchronicobstructivepulmonarydisease AT kimdeogkyeom roleofphosphodiesterase4inhibitorsinchronicobstructivepulmonarydisease |